Hepatitis C

P92 CD161+ γ-δ T cells: defining their role in patients with and without chronic hepatitis C
N Rajoriya, C Willberg, B Seigal, YuHoi Kang, J Phillips-Hughes, J Collier, E Barnes, R Thimme, P Klenerman

Gut Sep 2011, 60 (Suppl 2) A43; DOI: 10.1136/gutjnl-2011-300857a.92
OP04 Synergistic influence of tapasin and HLA class I protection against chronic Hepatitis C virus infection
S Ashraf, S Knapp, C Becford-Tackoir, C Brooks, A-M Little, G Alexander, M Cramp, S I Khakoo

Gut Sep 2011, 60 (Suppl 2) A51-A52; DOI: 10.1136/gutjnl-2011-300857b.4
High dose interferon treatment in chronic hepatitis C.
S Iino

Gut Jan 1993, 34 (2 Suppl) S114-S118; DOI: 10.1136/gut.34.2_Suppl.S114
Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v high dose treatment monitored by biochemical and virological markers (interim analysis). Benelux Multicentre Trial Study Group.
Gut Jan 1993, 34 (2 Suppl) S119-S120; DOI: 10.1136/gut.34.2_Suppl.S119
Interferon alfa for chronic hepatitis C in haemophiliacs.
M Makris, F E Preston, D R Triger, J C Underwood, L Westlake, M I Adelman

Gut Jan 1993, 34 (2 Suppl) S121-S123; DOI: 10.1136/gut.34.2_Suppl.S121
Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients.
D Bresters, E P Mauser-Bunschoten, H T Cuypers, J H Han, P L Jansen, R A Chamuleau, M Houghton, H W Reesink

Gut Jan 1993, 34 (2 Suppl) S124-S125; DOI: 10.1136/gut.34.2_Suppl.S124
STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?
T Asselah, L Rubbia-Brandt, P Marcellin, F Negro

Gut Jan 2006, 55 (1) 123-130; DOI: 10.1136/gut.2005.069757
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C
Robert J Fontana, Jules L Dienstag, Herbert L Bonkovsky, Richard K Sterling, Deepa Naishadham, Zachary D Goodman, Anna S F Lok, Elizabeth C Wright, Grace L Su, the HALT-C Trial Group

Gut Oct 2010, 59 (10) 1401-1409; DOI: 10.1136/gut.2010.207423
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C
T Asselah, N Boyer, M-C Guimont, D Cazals-Hatem, F Tubach, K Nahon, H Daïkha, D Vidaud, M Martinot, M Vidaud, C Degott, D Valla, P Marcellin

Gut Nov 2003, 52 (11) 1638-1643; DOI: 10.1136/gut.52.11.1638
μ-Opioid receptor activation prevents acute hepatic inflammation and cell death
Dania Chakass, David Philippe, Edmone Erdual, Sébastien Dharancy, Mathilde Malapel, Caroline Dubuquoy, Xavier Thuru, Jerome Gay, Claire Gaveriaux-Ruff, Pierre Dubus, Philippe Mathurin, Brigitte L Kieffer, Pierre Desreumaux, Mathias Chamaillard

Gut Jul 2007, 56 (7) 974-981; DOI: 10.1136/gut.2006.105122

Main menu

Hepatitis C

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Hepatitis C

Pages